These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 26563758

  • 1. Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation.
    Wang S, Su X, Bai H, Zhao J, Duan J, An T, Zhuo M, Wang Z, Wu M, Li Z, Zhu J, Wang J.
    J Hematol Oncol; 2015 Nov 12; 8():127. PubMed ID: 26563758
    [Abstract] [Full Text] [Related]

  • 2. Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs.
    Leonetti A, Capula M, Minari R, Mazzaschi G, Gregori A, El Hassouni B, Papini F, Bordi P, Verzè M, Avan A, Tiseo M, Giovannetti E.
    Cells; 2021 Jun 16; 10(6):. PubMed ID: 34208765
    [Abstract] [Full Text] [Related]

  • 3. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F, Diao XY, Zhang X, Shao Q, Feng YF, An X, Wang HY.
    Cancer Commun (Lond); 2019 Mar 02; 39(1):7. PubMed ID: 30823937
    [Abstract] [Full Text] [Related]

  • 4. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY, Liu YN, Wu SG, Hsu CL, Chang TH, Tsai MF, Lin YT, Shih JY.
    Cancer Biomark; 2020 Mar 02; 28(3):351-363. PubMed ID: 32417760
    [Abstract] [Full Text] [Related]

  • 5. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
    Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A.
    Clin Transl Oncol; 2011 Nov 02; 13(11):812-8. PubMed ID: 22082647
    [Abstract] [Full Text] [Related]

  • 6. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS, Raffeld M, Moon YW, Xi L, Bianco C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, Subramaniam D, Mok T, Rosell R, Luo J, Salomon DS, Wang Y, Giaccone G.
    J Clin Invest; 2014 Jul 02; 124(7):3003-15. PubMed ID: 24911146
    [Abstract] [Full Text] [Related]

  • 7. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI.
    Ann Oncol; 2013 Aug 02; 24(8):2080-7. PubMed ID: 23559152
    [Abstract] [Full Text] [Related]

  • 8. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P, Cao L, Chen X, Jing R, Yue W.
    BMC Cancer; 2019 Dec 10; 19(1):1203. PubMed ID: 31823748
    [Abstract] [Full Text] [Related]

  • 9. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ, Drilon A, Santini FC.
    Lung Cancer; 2019 Nov 10; 137():113-122. PubMed ID: 31568888
    [Abstract] [Full Text] [Related]

  • 10. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.
    Leonetti A, Assaraf YG, Veltsista PD, El Hassouni B, Tiseo M, Giovannetti E.
    Drug Resist Updat; 2019 Jan 10; 42():1-11. PubMed ID: 30544036
    [Abstract] [Full Text] [Related]

  • 11. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG, Lee CH, Lee WJ, Shin DH, Roh MS.
    Diagn Pathol; 2015 Jul 12; 10():99. PubMed ID: 26170125
    [Abstract] [Full Text] [Related]

  • 12. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M, Jaipuria J, Mattoo S, Dhandha S, Khatri M.
    Clin Oncol (R Coll Radiol); 2022 Nov 12; 34(11):e451-e462. PubMed ID: 35810049
    [Abstract] [Full Text] [Related]

  • 13. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.
    Mayo-de-Las-Casas C, Jordana-Ariza N, Garzón-Ibañez M, Balada-Bel A, Bertrán-Alamillo J, Viteri-Ramírez S, Reguart N, Muñoz-Quintana MA, Lianes-Barragan P, Camps C, Jantús E, Remon-Massip J, Calabuig S, Aguiar D, Gil ML, Viñolas N, Santos-Rodríguez AK, Majem M, García-Peláez B, Villatoro S, Pérez-Rosado A, Monasterio JC, Ovalle E, Catalán MJ, Campos R, Morales-Espinosa D, Martínez-Bueno A, González-Cao M, González X, Moya-Horno I, Sosa AE, Karachaliou N, Rosell R, Molina-Vila MA.
    Ann Oncol; 2017 Sep 01; 28(9):2248-2255. PubMed ID: 28911086
    [Abstract] [Full Text] [Related]

  • 14. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.
    BMC Med; 2012 Mar 21; 10():28. PubMed ID: 22436374
    [Abstract] [Full Text] [Related]

  • 15. Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.
    Haque I, Kawsar HI, Motes H, Sharma M, Banerjee S, Banerjee SK, Godwin AK, Huang CH.
    Int J Mol Sci; 2020 Dec 06; 21(23):. PubMed ID: 33291316
    [Abstract] [Full Text] [Related]

  • 16. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
    Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB.
    Sci Transl Med; 2013 Dec 18; 5(216):216ra177. PubMed ID: 24353160
    [Abstract] [Full Text] [Related]

  • 17. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Otsubo K, Sakai K, Takeshita M, Harada D, Azuma K, Ota K, Akamatsu H, Goto K, Horiike A, Kurata T, Nakagaki N, Nosaki K, Iwama E, Nakanishi Y, Nishio K, Okamoto I.
    Oncologist; 2019 Aug 18; 24(8):1022-1026. PubMed ID: 31023862
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
    Imai H, Minemura H, Sugiyama T, Yamada Y, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato K, Gunma-Ibaraki-Fukushima-Tochigi (GIFT) Group.
    Cancer Chemother Pharmacol; 2018 Jul 18; 82(1):119-127. PubMed ID: 29737372
    [Abstract] [Full Text] [Related]

  • 19. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y, Wang H, He C.
    J Cancer Res Clin Oncol; 2021 Dec 18; 147(12):3653-3664. PubMed ID: 34661758
    [Abstract] [Full Text] [Related]

  • 20. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H, Azuma K, Sakai K, Kawahara A, Yamada K, Tokito T, Okamoto I, Nishio K, Hoshino T.
    Oncotarget; 2015 Oct 13; 6(31):30850-8. PubMed ID: 26334838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.